```
prompt_version: stage1-v15-20260331

target_title:   Asymmetric Synthesis of Quaternary Hydantoins via a Palladium-Catalyzed Aza-Heck Cyclization
target_authors: Ellie A. Meck, Humair M. Omer, Montana J. Edwards, Temidayo D. Idowu, Mariah L. Murray, Katerina M. Korch, Donald A. Watson
target_start:   page 44692: [REDACTED: paper boundary quote; see Tier 9]
target_end:     end of document

[Turn 1: Agent V1]
field: Asymmetric synthesis and organometallic catalysis (enantioselective Pd-catalyzed heterocycle formation, aza-Heck reactions)
field_rationale: BIB-3 (JACS) and BIB-1 (Pd-catalyzed asymmetric aza-Heck cyclization to quaternary hydantoins) place the paper in asymmetric synthesis via organometallic catalysis; S0-4 specifies Pd(OAc)₂/phosphoramidite ligand, HTE optimization, and isolated yield/ee as the primary performance metrics.

V1-Q1
loc: P44693, Scheme 2 caption and text*
quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: Scheme 2 shows only "selected examples[REDACTED: substantial verbatim quotation; see Tier 9]unique effectiveness"?
severity: medium
inference_tier: T1

V1-Q2
loc: P44693, Table 1*
quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: Table 1 optimization yields are NMR assay yields at 0.1 mmol scale; the scope table (Scheme 3) uses isolated yields at 0.5 mmol scale. The relationship between these two yield types is not quantified — is the gap between 94% assay yield (entry 5) and the scope-level isolated yields systematic, or does it vary by substrate? The scale-up factor and purification losses are not disclosed.
severity: medium
inference_tier: T1

V1-Q3
loc: P44693, Table 1, entries 3 and 4*
quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: Entry 3 (10 mol% Pd, 25°C) gives 97% yield and 90% ee, while entry 4 (5 mol% Pd, 25°C) gives 85% yield and 98% ee. The optimal selected conditions (entry 5: 5 mol% Pd, 40°C) give 94% yield and 98% ee. Why is 40°C chosen as optimal over 25°C (entry 3) when the latter gives higher yield? The choice of 40°C over 25°C is not rationalized beyond "optimal conditions were found."
severity: medium
inference_tier: T1

V1-Q4
loc: P44693, Scheme 2 and text*
quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: The diastereomeric ligand (S-BINOL/R-aminoindane) gives much lower yield and ee, but the specific values are not reported. What ee and yield did this diastereomeric ligand give, and were other matched/mismatched BINOL/aminoindane combinations tested?
severity: medium
inference_tier: T1

V1-Q5
loc: P44693–44694, Scheme 3*
quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: For the bromide substrate (10), what yield was obtained and what byproducts were identified? "Significantly reduced" is not quantified, and the identity of the competitive Ar–Br activation byproducts is not disclosed. This limits assessment of the method's compatibility with halide functional groups.
severity: medium
inference_tier: T1

V1-Q6
loc: P44694, Scheme 3*
quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: Yields and ee values for products 18 and 19 at both temperatures are not given in the main text — only comparative descriptions ("high yield, somewhat lower ee"; "higher ee, more modest yield"). What are the actual yield and ee values at both 40°C and 75°C for substrates 18 and 19?
severity: high
inference_tier: T1

V1-Q7
loc: P44694, Scheme 3*
quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: The yields and ee values for N-alkyl substituted products 21, 22, 23, and 24 are not given in the main text — only described as "high yield with excellent ee," "lower yield and enantioselectivity," and "dramatic recovery." What are the actual numerical values for these products, and are the reactions run at rt (as stated in footnote 16) or at 40°C?
severity: high
inference_tier: T1

V1-Q8
loc: P44694, Scheme 3, footnote b*
quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: Some products in Scheme 3 use NMR yield at 0.1 mmol scale (footnote b) rather than isolated yield at 0.5 mmol scale. Which specific products are reported as NMR yields, and why were these substrates not run at 0.5 mmol scale for isolated yield? The footnote b designation is not individually assigned to specific products in the scheme as described in the main text.
severity: medium
inference_tier: T1

V1-Q9
loc: P44693–44694, Scheme 3*
quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: The gram-scale result for 5 is described as "similar yield and enantioselectivity" without reporting specific values. What yield and ee were obtained at gram scale, and what substrate quantity (in mmol or grams) was employed?
severity: medium
inference_tier: T1

V1-Q10
loc: P44694, eq 2*
quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: Absolute stereochemistry is assigned by comparison with a known compound (25 = known (S)-stereoisomer) after CAN deprotection. What is the specific optical rotation or spectral data used for this assignment, and which literature source for (S)-25 is used? The identity of the reference compound is not cited in the main text.
severity: high
inference_tier: T1

V1-Q11
loc: P44694, Scheme 4*
quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: Aza-Wacker byproduct 26 is observed at 5% for model substrate 4. For how many other substrates in Scheme 3 was aza-Wacker byproduct detected, and what were the byproduct levels? The statement [REDACTED: substantial verbatim quotation; see Tier 9] is qualitative.
severity: medium
inference_tier: T1

V1-Q12
loc: P44694–44695, Scheme 5*
quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: With the standard ligand (L1), the mephenytoin precursor 29 is obtained in only 43% yield and 70% ee — a significant drop from the typical 87% yield and 98% ee for compound 5. What structural feature of substrate 28 (N-methyl, C5-phenyl/methyl substitution) causes this performance gap, and was substrate optimization for mephenytoin synthesis (e.g., N-protecting group, alkene substitution) attempted before switching to ligand L9?
severity: high
inference_tier: T2 [paper-grounded inference]

V1-Q13
loc: P44693, eq 1 and associated text*
quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: "A variety of catalytic conditions" were screened for unprotected substrate 1 without success, but the specific conditions tried (temperature range, ligands, additives, solvents) are not described. What was the scope of conditions screened, and is the failure due solely to conformational factors or also to N-H coordination to Pd?
severity: medium
inference_tier: T1

V1-Q14
loc: P44694, Scheme 3, footnote 23*
quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: Substrates with both nitrogens alkyl-substituted fail to cyclize, but only a footnote reference to SI is provided. What structural features of the doubly N-alkylated substrate prevent cyclization — steric effects, inability to form the reactive N-metalated intermediate, or electronic effects?
severity: medium
inference_tier: T1

V1-Q15
loc: P44695, Figure 3*
quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: The proposed mechanism (Figure 3) is a schematic only — no specific Pd oxidation state assignments, no intermediate identities, and no rationale for N-O bond oxidative addition selectivity over competing pathways are given. Is oxidative addition into the N-O bond the established precedent for phosphoramidite-Pd systems, or is it inferred by analogy to the Watson group's prior work on O-phenyl hydroxamic esters?
severity: medium
inference_tier: T2 [paper-grounded inference]
```

---

> **Tier 8 redaction notice**: This file is a redacted copy of the corresponding Tier 3 / Tier 9 output. Verbatim source-paper quotations have been replaced by `[REDACTED: see source paper §<loc>; full text retained in Tier 9 reviewer-only deposit]` markers, preserving location references and our own analytical content. Bibliographic fields (title, authors, journal, year, DOI), analytical labels (`evidence_chain:` with B-/U-/A-/C- internal IDs), short technical terms, and our own analytical text are not redacted. The redaction was applied by `scripts/redact_for_tier8.py` and, for this version, by `scripts/build_paperA_R1_public.py` with `scripts/redact_source_ngram_runs.py` (scripts of the project repository; they are not deposited).
